Completed
PHASE1
INTERVENTIONAL
NCT03235778
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 2. To evaluate the pharmacokinetic characteristics in healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose
Interventions
Name:
Felbinac Trometamol Injection
Type:
DRUG
Description:
Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Name:
Placebo
Type:
DRUG
Description:
Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Primary Outcomes
Measure:
Tolerance evaluation index
TimeFrame:
up to 48.5 hours
Description:
percent of subjects with adverse reactions
Trial Information
NCT ID
NCT03235778
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Yiling Pharmaceutical Inc.
Last Updated
December 15, 2025